Citadel Advisors’s Cytokinetics CYTK Stock Holding History

Citadel Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.6M	Buy	145,700 +89,400	+159%	+$5.68M	﹤0.01%	3317
2025 Q4	$3.58M	Sell	56,300 -600	-1%	-$37.3K	﹤0.01%	4844
2025 Q3	$3.13M	Buy	56,900 +1,800	+3%	+$74.2K	﹤0.01%	5233
2025 Q2	$1.82M	Buy	55,100 +6,900	+14%	+$240K	﹤0.01%	5874
2025 Q1	$1.94M	Sell	48,200 -171,200	-78%	-$7.87M	﹤0.01%	5594
2024 Q4	$10.3M	Buy	219,400 +52,600	+32%	+$2.73M	﹤0.01%	2943
2024 Q3	$8.81M	Buy	166,800 +25,600	+18%	+$1.43M	﹤0.01%	3118
2024 Q2	$7.65M	Sell	141,200 -417,100	-75%	-$25.2M	﹤0.01%	3151
2024 Q1	$39.1M	Sell	558,300 -285,700	-34%	-$22.1M	0.01%	1411
2023 Q4	$70.5M	Buy	844,000 +762,200	+932%	+$27.6M	0.01%	913
2023 Q3	$2.41M	Buy	81,800 +39,300	+92%	+$1.31M	﹤0.01%	4878
2023 Q2	$1.39M	Buy	42,500 +1,100	+3%	+$40.7K	﹤0.01%	5815
2023 Q1	$1.46M	Sell	41,400 -29,300	-41%	-$1.2M	﹤0.01%	5971
2022 Q4	$3.24M	Buy	70,700 +29,700	+72%	+$1.28M	﹤0.01%	4627
2022 Q3	$1.99M	Sell	41,000 -6,000	-13%	-$289K	﹤0.01%	5607
2022 Q2	$1.85M	Buy	47,000 +29,800	+173%	+$1.2M	﹤0.01%	5694
2022 Q1	$633K	Sell	17,200 -15,300	-47%	-$544K	﹤0.01%	8819
2021 Q4	$1.48M	Sell	32,500 -12,600	-28%	-$486K	﹤0.01%	6914
2021 Q3	$1.61M	Buy	45,100 +8,000	+22%	+$236K	﹤0.01%	6907
2021 Q2	$734K	Sell	37,100 -35,000	-49%	-$822K	﹤0.01%	9144
2021 Q1	$1.68M	Sell	72,100 -10,700	-13%	-$228K	﹤0.01%	6830
2020 Q4	$1.72M	Sell	82,800 -28,100	-25%	-$514K	﹤0.01%	5676
2020 Q3	$2.4M	Buy	110,900 +39,100	+54%	+$915K	﹤0.01%	4389
2020 Q2	$1.69M	Sell	71,800 -36,800	-34%	-$690K	﹤0.01%	4866
2020 Q1	$1.28M	Buy	108,600 +48,100	+80%	+$614K	﹤0.01%	4901
2019 Q4	$642K	Buy	60,500 +44,800	+285%	+$460K	﹤0.01%	6398
2019 Q3	$179K	Sell	15,700 -10,100	-39%	-$127K	﹤0.01%	8213
2019 Q2	$290K	Buy	25,800 +3,800	+17%	+$36.6K	﹤0.01%	7633
2019 Q1	$178K	Buy	+22,000	New	+$162K	﹤0.01%	8291
2018 Q4	–	Sell	-15,900	Closed	-$157K	–	9205
2018 Q3	$157K	Buy	15,900 +5,000	+46%	+$40.1K	﹤0.01%	8365
2018 Q2	$90K	Sell	10,900 -10,300	-49%	-$85.7K	﹤0.01%	8280
2018 Q1	$153K	Sell	21,200 -10,100	-32%	-$86.6K	﹤0.01%	7524
2017 Q4	$255K	Sell	31,300 -2,800	-8%	-$31.8K	﹤0.01%	6713
2017 Q3	$494K	Buy	34,100 +20,900	+158%	+$285K	﹤0.01%	5349
2017 Q2	$160K	Sell	13,200 -7,300	-36%	-$101K	﹤0.01%	6698
2017 Q1	$263K	Buy	20,500 +6,800	+50%	+$79.5K	﹤0.01%	6080
2016 Q4	$166K	Buy	13,700 +2,500	+22%	+$26.5K	﹤0.01%	6434
2016 Q3	$103K	Sell	11,200 -6,200	-36%	-$64.7K	﹤0.01%	6642
2016 Q2	$165K	Buy	17,400 +4,800	+38%	+$39.4K	﹤0.01%	5960
2016 Q1	$89K	Sell	12,600 -1,500	-11%	-$11K	﹤0.01%	6075
2015 Q4	$147K	Sell	14,100 -2,700	-16%	-$26.5K	﹤0.01%	6231
2015 Q3	$112K	Buy	16,800 +8,100	+93%	+$55.3K	﹤0.01%	6843
2015 Q2	$58K	Buy	8,700 +100	+1%	+$656	﹤0.01%	7563
2015 Q1	$58K	Buy	8,600 +1,100	+15%	+$8.21K	﹤0.01%	7288
2014 Q4	$60K	Buy	7,500 +2,400	+47%	+$10.3K	﹤0.01%	7061
2014 Q3	$18K	Sell	5,100 -13,800	-73%	-$58K	﹤0.01%	7519
2014 Q2	$90K	Buy	18,900 +13,000	+220%	+$79.3K	﹤0.01%	6309
2014 Q1	$56K	Buy	+5,900	New	+$53.4K	﹤0.01%	6683

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citadel Advisors's CYTK Position: Q1 2026 in Review

Citadel Advisors reduced its Cytokinetics (CYTK) stake by 5.4% in Q1 2026, selling an estimated $4.01M and leaving 1,099,858 shares worth $72.5M. The position accounts for 0.01% of the portfolio, ranked #1052.

Citadel Advisors first reported a position in CYTK in Q1 2014 and has held it in 45 quarters since. The position peaked at $182M in Q2 2022. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

Citadel Advisors held 1,099,858 shares of Cytokinetics worth $72.5M as of Q1 2026.
Citadel Advisors sold 63,079 Cytokinetics shares in Q1 2026, an estimated $4.01M.
Cytokinetics made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1052 holding.
Citadel Advisors first reported a position in Cytokinetics in Q1 2014 and has held it in 45 quarters since.
Citadel Advisors's Cytokinetics position peaked at $182M in Q2 2022.
439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.